Head to Head Review: biote (NASDAQ:BTMD) vs. GlucoTrack (NASDAQ:GCTK)

biote (NASDAQ:BTMD) and GlucoTrack (NASDAQ:GCTK) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.

Valuation & Earnings

This table compares biote and GlucoTrack”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$195.65 million	0.62	$3.16 million	$0.79	3.39
GlucoTrack	N/A	N/A	-$22.60 million	($34.62)	-0.19

biote has higher revenue and earnings than GlucoTrack. GlucoTrack is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

21.7% of biote shares are held by institutional investors. Comparatively, 10.9% of GlucoTrack shares are held by institutional investors. 24.0% of biote shares are held by company insiders. Comparatively, 0.7% of GlucoTrack shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for biote and GlucoTrack, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	1	1	1	0	2.00
GlucoTrack	1	0	0	0	1.00

biote presently has a consensus price target of $6.00, suggesting a potential upside of 124.30%. Given biote’s stronger consensus rating and higher probable upside, equities research analysts clearly believe biote is more favorable than GlucoTrack.

Volatility and Risk

biote has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Comparatively, GlucoTrack has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500.

Profitability

This table compares biote and GlucoTrack’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
biote	15.73%	-21.00%	18.26%
GlucoTrack	N/A	N/A	-352.05%

Summary

biote beats GlucoTrack on 12 of the 13 factors compared between the two stocks.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.

About GlucoTrack

GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.